Citations

Clear

1575 citation(s) found for "Im, Gene".

FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.
Bahleda, Rastilav, Furuse, Junji , Moehler, Markus, Oh, Do‐Youn , Chang, Heung-Moon, Kelley, Robin Kate , Javle, Milind , Uboha, Nataliya V. , Klümpen, Heinz‐Josef , O’Dwyer, Peter J. , Morizane, Chigusa , Huang, Jerry, Goyal, Lipika , Furuse, Junji , Valle, Juan W. , Borad, Mitesh J. , Chen, Li‐Tzong , Li, Daneng , Bridgewater, John

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: TPS468-TPS468

10.1200/jco.2019.37.4_suppl.tps468 Get It

TPS468 Background: Intrahepatic cholangiocarcinoma (iCCA) is a cancer arising from the intrahepatic bile duct. Standard treatment of unresectable, recurrent, or metastatic iCCA is with cytotoxic chemotherapy. FGFR2 gene fusions have been identified as oncogenic drivers in 10–20% of iCCA tumors, but no targeted agents have been established to date. TAS-120 is an investigational irreversible FGFR1–4 inhibitor in development as a once-daily oral treatment for iCCA. Based on initial studies in multiple tumor types expressing FGFR abnormalities, iCCA was identified as a tumor type with potential susceptibility to FGFR inhibition and high unmet need. A phase I portion of the trial with an iCCA expansion cohort demonstrated tolerability and preliminary evidence of clinical efficacy with TAS-120 as a continuous, once-daily oral treatment in patients with iCCA. The most common AEs in the phase I portion of the trial were hyperphosphatemia, a mechanism-based on-target side effect, cutaneous AEs, and gastrointestinal AEs. The phase I portion of the study is continuing to enroll, and final results are anticipated in early 2019. Based on preliminary findings, a phase II portion of the study (FOENIX-101; clinicaltrials.gov registration NCT02052778) has been initiated. Methods: The phase II portion of the trial is a global, single-arm study of TAS-120 in patients with iCCA harboring FGFR2 gene rearrangements. The study will enroll approximately 100 adult patients with locally advanced or metastatic iCCA that progressed after ≥ 1 systemic therapies and with an ECOG PS of 0 or 1. Prior systemic therapy must include gemcitabine plus platinum-based chemotherapy. Screening for FGFR2 gene rearrangements will be performed at a central laboratory. The primary endpoint is objective response rate based on RECIST v1.1. Secondary endpoints include duration of response, disease control rate, overall survival, progression-free survival, safety, and health-related quality of life. Clinical trial information: NCT02052778.
Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).
Hall, Michael J. , Bodor, J. Nicholas , Xiu, Joanne , Goldberg, Richard M. , Worrilow, William M. , Hwang, Jimmy J., Kim, Edward S. , Lenz, Heinz‐Josef , Shields, Anthony F. , Salem, Mohamed E. , Feldman, Rebecca A. , Grothey, Axel , Raghavan, Derek , Marshall, John L , Korn, Wolfgang Michael

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 505-505

10.1200/jco.2019.37.4_suppl.505 Get It

505 Background: MSI is a tumor biomarker for immunotherapy efficacy that is closely associated w/deficient MMR, and is also variably associated w/somatic muts of the MMR genes, loss of MMR protein expression by immunohistochemistry (IHC), and high TMB. Germ-line muts (Lynch syndrome/LS) in the 4 MMR genes are recognized to have distinct cancer spectrums/penetrance in LS, yet across all tumors, gene-specific variability in MMR IHC, MMR muts, and TMB is understudied. Methods: Results of TGPs performed by Caris Lifesciences (2015-17) were analyzed in colorectal (CRC), endometrial (EC) and all other cancers/tumors (OT) as: 1) all MSI-H tumors (n = 1057) and 2) all tumors w/ ≥1 mut in an MMR gene (n = 470). A subset of cases had IHC for MMR protein and PD-L1 expression. MSI and TMB were determined by NGS. Results: Characteristics of MSI-H tumors and tumors w/ ≥1 MMR mut are seen in the Table. A single MSH6 mut [F1088fs] in a coding microsatellite represented 31% of all MMR muts detected. F1088fs was found in 58% tumors w/MLH1/PMS2 loss (IHC) but only 25% w/MSH2/MSH6 loss (p < 0.001), was more commonly seen in EC vs CRC/OT (p < 0.001), and was negatively associated w/somatic POLE mut (p = 0.002). Distinct mut signatures in the MMR genes (e.g. GLUàSTOP) were seen in tumors w/POLE muts and DNA repair genes. Conclusions: MSI-H and MMR mutated tumors demonstrate marked gene-specific heterogeneity in IHC patterns, TMBs, and somatic muts that may be relevant to treatment selection, resistance, and response. [Table: see text]
Familial chronic megacolon presenting in childhood or adulthood: Seeking the presumed gene association
Camilleri, Michael , Wieben, Eric D. , Eckert, Deborah J., Carlson, Paula, O’Dwyer, Ralph Hurley , Gibbons, Denys , Klee, Eric W. , Wieben, Eric, Eckert, Deborah, Hurley O'Dwyer, Ralph, Acosta, Andrés

Mayo Clinic

Neurogastroenterology & Motility | January 21, 2019 | Volume: 31 | Issue: 4 | Pages: No page available

10.1111/nmo.13550 | PMID 30663199 Get It

AbstractObjectiveWe identified a pedigree over five generations with 49 members, some of whom had chronic megacolon presenting in adolescence or adulthood. We aimed to assess the genetic cause of chronic megacolon through clinical and DNA studies.DesignAfter ethical approval and informed consent, family members provided answers to standard bowel disease questionnaires, radiological or surgical records, and DNA (buccal mucosal scraping). Exome DNA sequencing of colon tissue or blood DNA from seven family members with colon or duodenal dilatation, or no megacolon (n = 1) was carried out. Sanger sequencing was performed in 22 additional family members to further evaluate candidate variants. The study focused on genes of potential relevance to enteric nerve (ENS) maturation and Hirschsprung's disease or megacolon, based on the literature (GFRA1, NKX2‐1, KIF26A, TPM3, ACTG2, SCN10A, and C17orf107 [CHRNE]) and other genetic variants that co‐segregated with megacolon in the six affected family members.ResultsInformation was available in all except five members alive at time of study; among 30 members who provided DNA, six had definite megacolon, one megaduodenum, seven significant constipation without bowel dilatation, and 16 normal bowel function by questionnaire. Among genes studied, SEMA3F (g.3:50225360A>G; c1873A>G) was found in 6/6 family members with megacolon. The SEMA3F gene variant was assessed as potentially pathogenic, based on M‐CAP in silico prediction. SEMA3F function is associated with genes (KIT and PDGFRB) that impact intestinal pacemaker function.ConclusionFamilial chronic megacolon appears to be associated with SEMA3F, which is associated with genes impacting enteric nerve or pacemaker function.
Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics
Mangaonkar, Abhishek A. , Patnaik, Mrinal M.

Mayo Clinic

ADVANCES IN CELL AND GENE THERAPY | January 16, 2019 | Volume: 2 | Issue: 2 | Pages: e48

10.1002/acg2.48 | PMID 31559392 Get It

Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens.
Kourelis, Taxiarchis , Dasari, Surendra , Theis, Jason D. , Kurtin, Paul J. , Zeldensrust, Stephen R, Ramı́rez-Alvarado, Marina , Gertz, Morie A. , Doǧan, Ahmet , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8605-8605

10.1200/jco.2014.32.15_suppl.8605 Get It

Response of the Injured Tendon to Growth Factors in the Presence or Absence of the Paratenon
Quirk, Nicholas , Müller-Lebschi, Julia A., Heisterbach, Patricia E., Dürselen, Lutz , Majewski, Martin , Evans, Christopher H. , Müller, Sebastian A. , Quirk, Nicholas P, Quirk, Nicholas , Müller, Sebastian

Mayo Clinic

The American Journal of Sports Medicine | December 14, 2018 | Volume: 47 | Issue: 2 | Pages: 462-467

10.1177/0363546518814534 | PMID 30550720 Get It

Background: The paratenon is important for Achilles tendon healing. There is much interest in the use of exogenous growth factors (GFs) as potential agents for accelerating the healing of damaged Achilles tendons. Purpose/Hypothesis: The present study used a rat model to study the responses of the injured Achilles tendon to GFs in the presence or absence of the paratenon. The hypothesis was that responses of the injured tendon to GFs would be lower in the absence of a paratenon. Study Design: Controlled laboratory study. Methods: A 4-mm defect was created in the right Achilles tendon of 60 skeletally mature rats, which were treated with a validated combination of GFs (bFGF, BMP-12, and TGF-β1). Animals were randomly assigned to the intact paratenon (IP) group or resected paratenon (RP) group. Healing was studied anatomically, mechanically, and histologically after 1, 2, and 4 weeks. Results: IP tendons showed improved healing compared with RP tendons. IP tendons were significantly stronger (32.2 N and 48.9 N, respectively) than RP tendons (20.1 N and 31.1 N, respectively) after 1 and 2 weeks. IP tendons did not elongate as much as RP tendons and had greater cross-sectional areas (18.0 mm 2 , 14.4 mm 2 , and 16.4 mm 2 , respectively) after 1, 2, and 4 weeks compared with RP tendons (10.5 mm 2 , 8.4 mm 2 , and 11.9 mm 2 , respectively). On histology, earlier collagen deposition and parallel orientation of fibrils were found for IP tendons. Conclusion: The paratenon is essential for efficient Achilles tendon healing. Healing with GFs in this Achilles tendon defect model was superior in the presence of the paratenon. Clinical Relevance: Biological approaches to tendon engineering using GFs are in vogue and have been shown to improve healing of the rat Achilles tendon, most likely by inducing progenitor cells located within the paratenon. Clinically, resection or incision of the paratenon has been proposed for wound closure. Our data demonstrate the fundamental importance of the paratenon, which therefore should be preserved during Achilles tendon repair, especially if augmented with products such as platelet-rich plasma or autologous conditioned serum that are rich in GFs.
Chronic Obstructive Pulmonary Disease Phenotype Dictates Cancer-Promoting Stromal Gene Expression Programs
Wendt, Chris H. , Sandri, Brian J. , Masvidal, Laìa , Murie, Carl , Bartish, Margarita , Avdulov, Svetlana, Higgins, LeeAnn, Larsson, Ola , Wendt, Chris H , Larsson, Ola , Markowski, Todd W. , Peterson, Mark, Bergh, Jonas , Yang, Ping , Rolny, Charlotte , Limper, Andrew H. , Griffin, Timothy J. , Bitterman, Peter B.

Mayo Clinic

Annals of the American Thoracic Society | December 14, 2018 | Volume: 15 | Issue: Supplement_4 | Pages: S290-S291

10.1513/annalsats.201806-421mg Get It

Abstract Rationale Chronic obstructive pulmonary disease (COPD) is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that stromal cells comprising the COPD lung contain pathological gene expression programs supporting oncogenesis. Objectives To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer. Methods Study subjects included patients with COPD with (n = 30) or without (n = 30) lung cancer across a spectrum of COPD severity. We conducted multi-omics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome. Results Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation impacting protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms driving these procancer translation programs differed on the basis of COPD severity. In mild or no COPD, the mammalian target of rapamycin pathway served as an upstream driver; whereas in advanced COPD, pathways downstream of pathological extracellular matrix emerged. Both the mammalian target of rapamycin and extracellular matrix gene expression programs paralleled activation of previously identified secretomes that can be independently induced and promote cancer initiation in mouse models. These included the senescence secretome in mild to no COPD and the ETS2 (erythroblast transformation-specific 2) secretome in moderate to severe COPD. Furthermore, in situ examination of COPD lung tissue documented stromal fibroblasts expressing key cancer-associated proteins from procancer secretomes including IL-6 (senescence secretome) in mild COPD and bone morphogenetic protein-1 (ETS2 secretome) in advanced COPD. Conclusions Two distinct stromal gene expression programs promoting cancer initiation are activated in patients with lung cancer depending on the severity of COPD as measured by lung function. Our work has implications both for screening strategies and personalized approaches to prevent cancer in COPD.
Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need
Quiroz, Yakeel T. , Albensi, Benedict C. , Astell, Arlene , Babiloni, Claudio , Bahar‐Fuchs, Alex , Bowman, Gene L. , Chételat, Gaël , Ciro, Carrie , Cohen, Ann D. , Dilworth‐Anderson, Peggye, Dreux, Simone, Edland, Steven D. , Esbensen, Anna J. , Ewers, Michael , Fargo, Keith N. , Fortea, Juan , González, Héctor M. , Gustafson, Deborah , Head, Elizabeth , Hendrix, James A. , Hofer, Scott M. , Johnson, Leigh , Jutten, Roos J. , Kilborn, Kerry, Martins, Ralph N. , Morris, Martha Clare , Murray, Melissa E. , Parra, Mario A. , Roe, Catherine M. , Santos, Octavio A. , Scarmeas, Nikolaos , Schneider, Lon S. , Schupf, Nicole , Sikkes, Sietske A.M. , Snyder, Heather M. , Sohrabi, Hamid R. , Strydom, André , Muñiz‐Terrera, Graciela , Teunissen, Charlotte E. , Lent, Debora Melo van , Weinborn, Michael , Wesselman, Linda M.P. , Arenaza-Urquijo, Eider, Teunissen, Charlotte E , Fortea, Juan , Murray, Melissa E , Babulal, Ganesh M. , Arenaza‐Urquijo, Eider M. , Bell, J. Simon , Brickman, Adam M. , Dodge, Hiroko Hayama , Evered, Lisbeth Anne , Gonzalez, Hector M , Lanctôt, Krista L. , Manly, Jennifer J. , Mielke, Michelle M. , Oh, Esther S , Rissman, Robert A. , Stern, Yaakov , Tang, Yi , Wilcock, Donna M. , Zetterberg, Henrik , O’Bryant, Sid E. , Head, Elizabeth , Cohen, Annie

Mayo Clinic

Alzheimer's & Dementia | December 13, 2018 | Volume: 15 | Issue: 2 | Pages: 292-312

10.1016/j.jalz.2018.09.009 | PMID 30555031 Get It

Abstract Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART ) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross‐PIA white paper that provides both a concise “state‐of‐the‐science” report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.
P4450A cardio-metabolic phenotype in carriers of NPPA (rs5086) and NPPB (rs198389) gene variants in the general population: the dominant role of ANP
Fuglestad, Anniken Jørlo , Sangaralingham, S. Jeson , Cannone, Valentina , Burnett, John C. , Fuglestad, A, Sangaralingham, S. Jeson , Scott, Christopher G.

Mayo Clinic

European Heart Journal | December 10, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy563.p4450 Get It

The King-Devick test in mixed martial arts: the immediate consequences of knock-outs, technical knock-outs, and chokes on brain functions
Hubbard, Ryan , Stringer, Gene, Peterson, Ken, Carneiro, Mario Roberto Filho Vaz, Savica, Rodolfo , Finnoff, Jonathan T. , Stringer, Gene C.

Mayo Clinic

Brain Injury | December 3, 2018 | Volume: 33 | Issue: 3 | Pages: 349-354

10.1080/02699052.2018.1553068 | PMID 30507317 Get It